--- title: "Infliximab for Acute Pancreatitis (RAPID-I): Phase 2b Randomised Double-Blind Trial Protocol" id: "bmj-open-14-randomised-treatment-of-acute-pancreatitis-with-infliximab-protocol-for-a" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-14-randomised-treatment-of-acute-pancreatitis-with-infliximab-protocol-for-a" content_type: "clinical_feed_article" specialty: "Gastroenterology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e118729?rss=1" published_at: "2026-09-18T12:04:54.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Infliximab for Acute Pancreatitis (RAPID-I): Phase 2b Randomised Double-Blind Trial Protocol ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-14-randomised-treatment-of-acute-pancreatitis-with-infliximab-protocol-for-a - **Specialty:** [Gastroenterology](https://medichelpline.com/clinical-feed/gastroenterology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e118729?rss=1) - **Published At:** 2026-09-18T12:04:54.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - This phase 2b, multicentre, double-blind, placebo-controlled trial (RAPID-I) will test the anti-TNF antibody **infliximab** in patients with **acute pancreatitis (AP)**, based on the role of **TNF-α** in AP pathophysiology. - Planned enrolment is 240 patients randomised 1:1:1 to a single infusion of 5 mg/kg, 10 mg/kg infliximab, or placebo, administered within 36 hours of hospital admission. - The primary endpoint is mean serum **C-reactive protein (CRP)** on trial days 2, 4 (±1 day) and 14 (±2 days), summarised as area under the curve (AUC); a 25% reduction in either active arm versus placebo is defined as clinically meaningful. - Key secondary endpoints cover pain scores, opioid requirements, nutritional deficit (days without solid food), decline in serum albumin (negative AUC), rise in neutrophils (AUC), cumulative SOFA-2 scores, local pancreatic injury on contrast-enhanced CT at day 14 (±7 days), infections, length of stay, mortality, and patient-reported outcomes at days 4, 14 and 90. - Economic evaluation will estimate cost-effectiveness using costs and quality-adjusted life years (QALYs) over 90 (±7) days. - Safety monitoring focuses on adverse events related to infliximab; additional mechanistic analyses include transcriptomic, cytokine and leukocyte profiling at baseline and the same CRP time points. - The trial includes two planned adaptive interim analyses. - Research Ethics Committee approval has been obtained (South Central - Oxford C Research Ethics Committee 18/SC/0262). Trial registration: NCT03684278. - Results will be disseminated via peer-reviewed publication and presentations at national and international meetings. ## Clinical Analysis & Structured Key Points Introduction Acute pancreatitis (AP) is an increasingly common cause of substantial morbidity and risk of mortality without licensed specific drug therapy. Because tumour necrosis factor α (TNF-α) contributes to AP, anti-TNF therapy may improve outcome from AP. This trial aims to test the efficacy, safety, cost-effectiveness and mechanism of action of the anti-TNF antibody infliximab in patients with AP. Methods and analysis Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a phase 2b trial designed to randomise 240 patients with AP to receive a single 5 mg/kg or 10 mg/kg infliximab or placebo infusion in a 1:1:1 ratio, initiated within 36 hours of hospital admission. The primary outcome is mean serum C-reactive protein (CRP) on trial days 2, 4 (±1 day) and 14 (±2 days) summated as area under the curve (AUC), with 25% reduction in either active arm compared with placebo considered clinically meaningful. Secondary outcomes include cumulative pain scores, opiate requirements, nutritional deficit (days without solid food), decline in serum albumin (negative AUC), rise in neutrophils (AUC), cumulative selective serial organ failure assessment (SOFA-2) scores, local pancreatic injury on contrast-enhanced CT scan (CECT day 14±7 days), infections, length of stay, mortality and patient reported outcome on days 4 (±1 day), 14 (±2 days) and 90 (±7 days). Cost-effectiveness will be based on costs and quality-adjusted life years over 90 (±7) days. Potential safety signals will be adverse events related to infliximab. Transcriptomic, cytokine and leucocyte profiles will be assessed at baseline and the same time points as CRP. Two adaptive interim analyses are planned. Ethics and dissemination The protocol has received Research Ethics Committee approval (South Central - Oxford C Research Ethics Committee 18/SC/0262). The findings will be disseminated through peer reviewed publication, national and international conferences and meetings. Trial registration number NCT03684278 . ## Related Clinical Research - [Drain-Fluid Proteomics Identifies Procedure-Specific Signatures of Postoperative Anastomotic Leaka](https://medichelpline.com/clinical-feed/medrxiv-10-longitudinal-drain-fluid-proteomics-reveals-procedure-specific-signatures-of.md) - [Cost-effective Chelex-100 Method for Genomic DNA Extraction from Zebrafish Tissues](https://medichelpline.com/clinical-feed/plos-one-6-a-rapid-and-cost-effective-chelex-100-resin-based-method-for-genomic-dna.md) - [Determinants of Gut Microbiome Composition and Response to a Short Shared-Living Dietary Intervent](https://medichelpline.com/clinical-feed/biorxiv-7-determinants-of-gut-microbiome-composition-and-its-response-to-a-dietary.md) - [Fluid Shear Stress Drives Mechanoadaptive Fibroblast Remodeling and Early Fibrogenesis Signatures](https://medichelpline.com/clinical-feed/biorxiv-17-ultrastructural-and-proteomic-signatures-of-mechanoadaptive-fibroblast.md) - [Association Between Helicobacter pylori Seropositivity and Dyslipidemia in General Health Checkup](https://medichelpline.com/clinical-feed/medrxiv-0-association-of-helicobacter-pylori-infection-and-dyslipidemia-among-individuals.md) ## Navigation - [← Back to Gastroenterology Feed](https://medichelpline.com/clinical-feed/gastroenterology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.